Выпуск
Anywhere DX CEO Nathalya Mamane on Building a $25 At-Home Strep Test
Inside Startup Investing with Chris Lustrino · 22 октября 2026 г. · 28 мин
Nathalya Mamane is the co-founder and CEO of Anywhere DX, and she's building the thing every parent has wished for at 9 p.m. on a Friday: an at-home strep test. Not a throat swab — the FDA won't allow one at home — but a saliva-based, single-use device that runs a lab-grade molecular test and shows a result in about 20 minutes, for under $25 with telehealth and a prescription built in. Nathalya joins Chris Lustrino to tell the story behind it: a mother of four, mid-MBA at Babson during COVID, watching a nurse in a hazmat suit swab her daughter through a car window and thinking, "Why can't we just do this at home?" What started as a strep test has become a platform the company plans to extend to UTIs, STIs and other infections with the same unmet need. She walks through what's already been de-risked on the bench — saliva cleanup and concentration, the LAMP amplification process, an internal heater, a readout you see with your own eyes — and the engineering challenge of fitting all of it into one disposable device at a sub-$5 cost. Her co-founder, Dr. Michael Mina, worked closely with the FDA on diagnostics during the pandemic, and the company is building to a 510(k) path it expects to clear with a few hundred samples in a single cold-and-flu season. In this episode: ● Why the rapid antigen test in your pediatrician's office misses so many early strep cases ● PCR vs. antigen tests, explained in plain English ● The $5 build cost and the $25 retail target — and why doctors' offices may want it too ● 510(k) vs. de novo: what each FDA route means and why Anywhere DX is on the easier one ● The ~$1.5–1.7M clinical and submission budget, and what the Wefunder round funds first ● Market size: roughly 50 million US strep tests a year, and only 12–14% come back positive ● Why she expects to commercialize through white-label and licensing partners ● Lessons from "the ugly duckling of life sciences" Guest: Nathalya Mamane, Co-founder & CEO, Anywhere DX Host: Chris Lustrino, Founder & CEO, Kingscrowd Anywhere DX is raising now. Kingscrowd rates Anywhere DX a 2.7 out of 5. To see the full analyst breakdown and discover how you can invest, visit kingscrowd.com. Inside Startup Investing is the only podcast where you can invest in every guest. Subscribe so you never miss a founder interview. Disclosure: This episode is for informational purposes only and is not investment advice or a recommendation to buy any security. Investing in early-stage companies is risky and illiquid, and you may lose your entire investment.